-
June 9, 2025 Lupin Foundation Flags off Mobile Medical Van in Palghar to Strengthen Non-Communicable Disease Care
-
June 7, 2025 Lupin Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets
-
May 26, 2025 Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology – Annual Meeting 2025
-
May 26, 2025 Lupin and SteinCares Enter into License and Supply Agreement for Ranibizumab in Latin America
-
May 20, 2025 Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers
-
May 15, 2025 Punita Lal Joins Lupin Board as Additional Director
-
May 15, 2025 Lupin Receives Approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg
-
May 14, 2025 Lupin FY2025 Results
-
May 13, 2025 Lupin Launches Tolvaptan Tablets in the U.S. with 180-Day Exclusivity
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications